MA41689A - Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine - Google Patents

Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine

Info

Publication number
MA41689A
MA41689A MA041689A MA41689A MA41689A MA 41689 A MA41689 A MA 41689A MA 041689 A MA041689 A MA 041689A MA 41689 A MA41689 A MA 41689A MA 41689 A MA41689 A MA 41689A
Authority
MA
Morocco
Prior art keywords
prevention
treatment
sleep disorders
dexmedetomidine formulation
dexmedetomidine
Prior art date
Application number
MA041689A
Other languages
English (en)
French (fr)
Inventor
Krishnan Nandabalan
Harsh Negi
Deepa Saini
Sameer Sharma
Frank Yocca
Original Assignee
Bioxcel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxcel Corp filed Critical Bioxcel Corp
Publication of MA41689A publication Critical patent/MA41689A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA041689A 2014-10-15 2015-10-14 Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine MA41689A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462064205P 2014-10-15 2014-10-15

Publications (1)

Publication Number Publication Date
MA41689A true MA41689A (fr) 2017-08-22

Family

ID=55747372

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041689A MA41689A (fr) 2014-10-15 2015-10-14 Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine

Country Status (5)

Country Link
US (3) US20170239221A1 (enExample)
EP (1) EP3206685B1 (enExample)
JP (4) JP2017534613A (enExample)
MA (1) MA41689A (enExample)
WO (1) WO2016061413A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202107367SA (en) 2016-12-31 2021-08-30 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
ES3004544T3 (en) 2018-06-27 2025-03-12 Bioxcel Therapeutics Inc Film formulations containing dexmedetomidine and methods of producing them
US20240024288A1 (en) 2019-07-19 2024-01-25 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN113827590A (zh) * 2020-06-08 2021-12-24 四川普锐特药业有限公司 右美托咪定在助眠药物制备中的应用
AU2022239873A1 (en) 2021-03-19 2023-11-02 Orion Corporation Tasipimidine formulations and use thereof
CN115197149B (zh) * 2021-04-02 2023-09-22 四川大学华西医院 一种5-苄基咪唑类化合物及其制备方法和用途
EP4364729A4 (en) * 2021-08-23 2024-11-27 Yichang Humanwell Pharmaceutical Co., Ltd. TRANSDERMAL COMPOSITION OF DEXMEDETOMIDINE, TRANSDERMAL PATCH AND METHOD OF PREPARATION AND USE THEREOF
IL318007A (en) 2022-07-27 2025-02-01 Universit?T Z?Rich Dexmedetocidin for the treatment of sleep disorders
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
KR102853305B1 (ko) * 2023-05-25 2025-09-01 가톨릭대학교 산학협력단 상추 추출물 및 대추 추출물을 유효성분을 함유하는 불면증 해소용 구강 붕해 필름 조성물
CN117771220B (zh) * 2024-02-28 2024-05-28 山东第二医科大学 一种右美托咪定中药多糖口溶膜剂及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20030022926A1 (en) * 2001-05-07 2003-01-30 Lavand'homme Patricia Method for treating neuropathic pain and pharmaceutical preparation therefor
US20050222270A1 (en) * 2004-02-26 2005-10-06 Olney John W Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
WO2007010242A1 (en) * 2005-07-18 2007-01-25 Imperial College Innovations Limited Use of a noradrenergic agonist, e.g. guanfacine, for the treatment of cognitive disorders
AU2007216320B2 (en) * 2006-02-13 2010-10-28 Orient Pharma (Samoa) Co., Ltd. Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
WO2008141264A1 (en) * 2007-05-10 2008-11-20 Novadel Pharma Inc. Anti-insomnia compositions and methods
PE20091084A1 (es) * 2007-12-07 2009-07-23 Schering Plough Healthcare Formulaciones farmaceuticas de fenilefrina y composiciones para absorcion transmucosal
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
EP3305281A1 (en) * 2009-05-15 2018-04-11 Recro Pharma, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
EP2521544A4 (en) * 2010-01-08 2013-08-21 Recro Pharma Inc TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHOD FOR THEIR USE
US8241661B1 (en) * 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
WO2013061161A2 (en) * 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
CA2858721C (en) * 2011-12-11 2021-03-16 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
TWI709417B (zh) * 2013-10-07 2020-11-11 美商帝國製藥美國股份有限公司 使用右美托咪啶經皮組成物用於治療注意力不足過動症、焦慮及失眠的方法及組成物

Also Published As

Publication number Publication date
JP2017534613A (ja) 2017-11-24
EP3206685A1 (en) 2017-08-23
US20250099430A1 (en) 2025-03-27
JP2021080276A (ja) 2021-05-27
EP3206685B1 (en) 2024-05-08
US20230414572A1 (en) 2023-12-28
WO2016061413A1 (en) 2016-04-21
EP3206685A4 (en) 2018-06-20
US20170239221A1 (en) 2017-08-24
JP2025092508A (ja) 2025-06-19
JP2023076465A (ja) 2023-06-01

Similar Documents

Publication Publication Date Title
IL256166B (en) Compounds for use in treating neuromuscular disorders
MA45192A (fr) Traitement d'association
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
IL247452A0 (en) Compounds for treatment of complement mediated disorders
EP3370748A4 (en) THERAPEUTIC MICROBIOTA FOR THE TREATMENT AND / OR PREVENTION OF FOOD ALLERGY
EP2875826A4 (en) COMPOSITION FOR PREVENTING OR TREATING SEPSIS
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
EP3274440A4 (en) Detecting esophageal disorders
MA39753A (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
IL262852A (en) Treatment of complement-mediated disorders
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
FR3011467B1 (fr) Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies
HUE037663T2 (hu) Kalcitonin mimetikumok betegségek és rendellenességek kezelésére
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3206685A4 (en) Prevention or treatment of sleep disorders using dexmedetomidine formulation
EP2870161A4 (en) OXABICYCLOHEPTANESE AND OXABICYCLOSES FOR THE TREATMENT OF REPERFUSION INJURIES
EP3370725A4 (en) PEDIATRIC DOSAGE FOR THE TREATMENT OF CANCER WITH AN EZH2 INHIBITOR
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP4223359C0 (en) Non-invasive device for treating gastro-esophageal reflux disease
IT201600121601A1 (it) Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP2950762A4 (en) PREVENTIVE AND TREATING NEUROPATHY
IL280227A (en) Arimoclomol for treating glucocerebrosidase associated disorders
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES